subscribeSubscribe
UK probes GLP-1 drugs` potential suicide risks

UK probes GLP-1 drugs` potential suicide risks
Angus Liu FIERCE PHARMA
27 Jul 2023
Share Share
Sanofi Aventis Adlyxin (Lixisenatide) Receives Approval in the U.S.

Sanofi Aventis Adlyxin (Lixisenatide) Receives Approval in the U.S.
FDA
10 Jun 2022
Share Share
Sanofi Ave Soliqua Insulin Glargine:Lixisenatide Receives Approval in the U.S.

Sanofi Ave Soliqua Insulin Glargine:Lixisenatide Receives Approval in the U.S.
FDA
10 Jun 2022
Share Share
SMC recommends Suliqua for restricted use in combination with metformin

SMC recommends Suliqua for restricted use in combination with metformin
PHARMIWEB
16 Apr 2020
Share Share
Sanofi talks up personalized diabetes care in patient-centric awareness push

Sanofi talks up personalized diabetes care in patient-centric awareness push
Beth Snyder Bulik FIERCE PHARMA
10 Jun 2019
Share Share
US FDA approves expanded use of Soliqua 100/33

US FDA approves expanded use of Soliqua 100/33
PHARMABIZ
28 Feb 2019
Share Share
Sanofi-Aventis’s Suliqua (insulin glargine/lixisenatide) Receives Approval In Europe

Sanofi-Aventis’s Suliqua (insulin glargine/lixisenatide) Receives Approval In Europe
EMA
30 Mar 2017
Share Share
Tetraphase antibiotic may reach up to $700 million in annual sales: CEO

Tetraphase antibiotic may reach up to $700 million in annual sales: CEO
Bill Berkrot  REUTERS
09 Feb 2017
Share Share
EU approval for Sanofi’s diabetes combo

EU approval for Sanofi’s diabetes combo
Selina McKee PHARMATIMES
18 Jan 2017
Share Share
EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand

EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand
GLOBENEWSWIRE
17 Jan 2017
Share Share